REV-ERB is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
== Prevalence and popularity == Globally, 14.3% of married or partnered women of reproductive age (15–49) use intrauterine contraception as their preferred method of family planning. A study found that female family planning providers choose LARC methods more often (41.7%) than the general public (12.1%). However, the adoption of IUDs varies significantly across different regions. In Asia, IUD is particularly popular, with 27% of contraceptive users relying on it, while in Oceania, the usage rate is much lower at 1.8%. Geographically, the majority of IUD users—over 80% worldwide—are concentrated in Asia, with nearly two-thirds (64%) of these users living in China, according to a 2011 United Nations review. IUD use is more prevalent in less developed regions (15.1% of women) compared to more developed regions (9.2% of women). Within continents, there are significant variations. For instance, in Europe, IUD use ranges from 5% in Southern Europe to 16–28% in countries like France and Scandinavia. In Africa, IUD use is relatively low in sub-Saharan regions (less than 2%) but higher in Northern Africa, particularly in countries such as Egypt (36.1%) and Tunisia (27.8%). In the United States, the use of IUDs increased from 0.8% in 1995 to 7.2% from the period of 2006 to 2014 and to 10.5% in a 2017-2019 survey. IUD usage rates are also influenced by ethnicity within the United States, with Hispanic women more likely to use IUD compared to Caucasian women. Among birth control methods, IUDs, along with other contraceptive implants, result in the greatest satisfaction among users.
7 December Storm Darragh: Hundreds of thousands are left without power, while travel is disrupted and many planned events are called off, as winds of up to 93 mph (150 km/h) hit much of the UK, along with heavy rain. A rare red weather warning is in place in Wales and south-west England, meaning the storm poses a risk to life. The deaths of two men are reported, in Birmingham and Lancashire, due to trees falling on vehicles. A 61-year-old Elizabeth line worker dies following a serious assault at Ilford railway station on 4 December. A 28-year-old man is charged with grievous bodily harm, affray, and possession of a prohibited offensive weapon. 8 December Prime Minister Sir Keir Starmer welcomes the Fall of the Assad regime in Syria, which he describes as "barbaric", and calls for the restoration of "peace and stability". Emma Pinchbeck, the new chief executive of the UK government's Climate Change Committee, says the UK is "not ready" for the kind of extreme weather brought by Storm Darragh. Prince William helps to serve lunch at The Passage, a London-based homeless charity he first visited with his mother as a boy. 9 December – The UK pauses asylum claims from Syrian refugees following the overthrow of Bashar al-Assad. 10 December The UK government recommends a 2.8% pay rise for public sector workers from April 2025. In response, the Unison trade union describes the offer as "barely above the cost of living". King Charles III presents the first Elizabeth Emblems, recognising public servants such as police officers and firefighters who died while on duty.
In the 1950s, shipping costs made up 33% of the price of oil transported from the Persian Gulf to the United States, but with the development of supertankers in the 1970s, the cost of shipping dropped to 5% of the price of Persian oil in the US. The share of the shipping cost on the final cost of the delivered commodity was less than 3% in 2010.
Sources: en.wikipedia.org
Amino acid score is used to determine if a protein is complete. It is used along with the measure of protein digestibility that refers to how well a given protein is digested, to compare the proportion of essential amino acids found in one protein to the proportion in a "reference protein" considered to be complete.
== Mechanism of action == Antipsychotic drugs such as haloperidol and chlorpromazine tend to block dopamine D2 receptors in the dopaminergic pathways of the brain. This means that dopamine released in these pathways has less effect. Excess release of dopamine in the mesolimbic pathway has been linked to psychotic experiences. Decreased dopamine release in the prefrontal cortex, and excess dopamine release in other pathways, are associated with psychotic episodes in schizophrenia and bipolar disorder. In addition to the antagonistic effects of dopamine, antipsychotics (in particular atypical antipsychotics) also antagonize 5-HT2A receptors. Different alleles of the 5-HT2A receptor have been associated with schizophrenia and other psychoses, including depression. Higher concentrations of 5-HT2A receptors in cortical and subcortical areas, in particular in the right caudate nucleus have been historically recorded. Typical antipsychotics are not particularly selective and also block dopamine receptors in the mesocortical pathway, tuberoinfundibular pathway, and the nigrostriatal pathway. Blocking D2 receptors in these other pathways is thought to produce some unwanted side effects that the typical antipsychotics can produce (see above). Antipsychotics were commonly classified on a spectrum of low potency to high potency, where potency referred to the ability of the drug to bind to dopamine receptors, and not to the effectiveness of the drug.
Tolkien learnt to paint and draw as a child and continued to do so all his adult life. From early in his writing career, the development of his stories was accompanied by drawings and paintings, especially of landscapes, and by maps of the lands in which the tales were set. He produced pictures to accompany the stories told to his own children, including those later published in Mr Bliss and Roverandom, and sent them elaborately illustrated letters purporting to come from Father Christmas. Although he regarded himself as an amateur, the publisher used the author's own cover art, his maps, and full-page illustrations for the early editions of The Hobbit. He prepared maps and illustrations for The Lord of the Rings, but the first edition contained only the maps, his calligraphy for the inscription on the One Ring, and his ink drawing of the Doors of Durin. Much of his artwork was collected and published in 1995 as a book: J. R. R. Tolkien: Artist and Illustrator. The book discusses Tolkien's paintings, drawings, and sketches and reproduces approximately 200 examples of his work. Catherine McIlwaine curated a major exhibition of Tolkien's artwork at the Bodleian Library, Tolkien: Maker of Middle-earth, accompanied by a book of the same name that analyses Tolkien's achievement and illustrates the full range of the types of artwork that he created.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.